Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in decision-analytic modelling for economic evaluation.

Milton C Weinstein1

  • 1Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115, USA.

Pharmacoeconomics
|October 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Component Clinical and Cost Outcomes Complementing Value of Information: Case Study of a Tuberculosis Diagnostics Clinical Trial.

PharmacoEconomics·2026
Same author

The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling study.

The lancet. HIV·2025
Same author

Clinical impact and cost-effectiveness of the WHO-recommended advanced HIV disease package of care.

The Lancet. Global health·2025
Same author

Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens.

PloS one·2025
Same author

Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling study.

medRxiv : the preprint server for health sciences·2023
Same author

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.

Journal of medical economics·2023
Same journal

Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia.

PharmacoEconomics·2026
Same journal

Applications of Structural Expert Elicitations for Economic Evaluations: A Systematic Review Update.

PharmacoEconomics·2026
Same journal

Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment.

PharmacoEconomics·2026
Same journal

A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.

PharmacoEconomics·2026
Same journal

Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.

PharmacoEconomics·2026
Same journal

Informing the Equitable Implementation of Hepatitis C Interventions: Cost-Effectiveness Modeling in Rural Populations of People Who Inject Drugs.

PharmacoEconomics·2026
See all related articles

Advancements in healthcare economic modeling include survival extrapolation, microsimulation, model calibration, and infectious disease transmission models. These methods enhance decision-analytic modeling for healthcare programs and economic evaluations.

Area of Science:

  • Health Economics
  • Decision Science
  • Mathematical Modeling

Background:

  • Rapid evolution in decision-analytic modeling for healthcare economic evaluations.
  • Increased computational power drives new modeling approaches.

Purpose of the Study:

  • To review four key developments in healthcare economic modeling.
  • To highlight advancements in survival extrapolation, microsimulation, model calibration, and transmission modeling.

Main Methods:

  • Survival extrapolation: exploring varied assumptions for outcome projection.
  • Microsimulation: utilizing probabilistic simulation (Monte Carlo) and discrete-event simulation for patient and system interactions.
  • Model calibration: employing numerical analysis and mathematical programming for evidence synthesis.

Related Experiment Videos

  • Transmission models: using differential equations for infectious disease analysis and cost-effectiveness.

    • Main Results:

    • No single optimal method for survival extrapolation is established.
    • Microsimulation, including discrete-event simulation, is increasingly practical for healthcare delivery and population transmission.
    • Model calibration offers new insights into disease processes.
    • Transmission models now integrate patient-level and population-level benefits for cost-effectiveness analysis.

    Conclusions:

    • Technological advances enable more complex and rapid healthcare simulations.
    • A key challenge is ensuring model interpretability for decision-makers.
    • Future modellers must balance advanced methods with clear communication of insights.